New drug evorpacept added to existing cancer treatment in clinical trial
"Tumor shrinkage rate was higher than in the control group, and treatment response lasted longer"

Seoul National University Bundang Hospital said on November 16 that a team led by Professor Lee Geunwook of its Department of Hematology and Oncology had found that a new treatment strategy blocking cancer cells' immune evasion signals could improve the effectiveness of cancer treatment in patients with metastatic gastric cancer.


The research team focused on the "don't eat me" signal that cancer cells use to evade attacks by immune cells. Some cancer cells use the CD47 protein on their surface to prevent macrophages, a type of immune cell, from eliminating them.


Lee Geunwook, professor of hematology and oncology at Seoul National University Bundang Hospital. Seoul National University Bundang Hospital.

Lee Geunwook, professor of hematology and oncology at Seoul National University Bundang Hospital. Seoul National University Bundang Hospital.

View original image

The team combined evorpacept, an investigational drug that blocks this signal, with trastuzumab, an existing targeted cancer drug. The approach works by using trastuzumab to mark cancer cells as targets and evorpacept to block their defensive signals, helping macrophages eliminate them.


A clinical trial involving 127 patients with HER2-positive metastatic gastric cancer at 49 institutions in 10 countries found that the objective response rate was 40.3% in the evorpacept combination group, higher than the 26.6% in the control group. The median duration for which tumor shrinkage was maintained was also about twice as long in the combination group, at 15.7 months, as in the control group, at 7.6 months.


The difference in effectiveness was even greater among patients whose tumors had both targets of the two drugs. An additional analysis of 48 patients with HER2-positive tumors and high CD47 expression found that the objective response rate in the combination group was 63.6%, substantially higher than the 23.1% in the control group. The duration for which tumor shrinkage was maintained was 25.5 months in the combination group and 8.4 months in the control group.


By contrast, the combination treatment showed no clear additional benefit in patients who did not meet both conditions. The research team suggested that the findings point to the potential of personalized immunotherapy, in which patients with the treatment targets are identified and given the drugs.



"We confirmed the potential of a new treatment strategy that supports the role of macrophages by combining a targeted cancer drug that identifies cancer cells with a drug that blocks their defensive signals," Professor Lee said. "We will verify its effectiveness in large-scale clinical trials and develop it into precision immunotherapy." The findings were recently published in the international journal Nature Medicine.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing